In the present study, we found that KRIBB11 (an HSF1 inhibitor) and HSF1 knock-down suppressed mevalonate pathway- and cholesterol biosynthesis-related genes and enzyme expression upon simvastatin treatment in HCC cells. This evidence concerns the gene HSF1 and hepatocellular carcinoma.